BioNTech leader: We should get used to living with coronavirus for the next 10 years
Get real time updates directly on you device, subscribe now.
BioNTech vaccine against coronavirus’s Micron mutation delayed. Ugur Sahin, head of the German nanotechnology company, told Bild television that the vaccine would be ready in April or May. He argued that the delay was due to the European Medicines Agency.
“Delivery of the vaccine against the Omicron variant is postponed to April or May,” said Ugur Sahin, head of the German biotechnology company BioNTech, in an interview with Bild TV.
Initially, the biotechnology company had announced that the delivery of the injectable preparation is scheduled for the end of March.
Sahin also stressed that we should get used to living with the coronavirus for the next 10 years.
#UPDATE The world is becoming “better prepared” to deal with future variants of the coronavirus, the CEO and co-founder of German vaccine-maker BioNTech tells @AFP as the company works on an Omicron-specific shothttps: //t.co/KetqDKOI9m pic.twitter.com/2ixQNyY2Eu
– AFP News Agency (@AFP) February 17, 2022
The cause of the delay is the European Medicines Agency, Sahin claims
However, according to Ugur Sahin, the reason for the delay in the vaccine is the European Medicines Agency (EMA). “EMA had to wait longer than planned for the data required for approval,” said Sahin, 56.
Competent European authorities had to investigate whether an “Omicron” mutant vaccine was still worthwhile. If necessary, BionTech could develop vaccines for new variants, he adds. He also points out that the situation with the coronavirus is no longer dramatic. “We should never expect to get rid of Covid disease,” he said.
“People are becoming more and more ‘better prepared’ to deal with future variants of the coronavirus,” Sahin told AFP.
“When the pandemic started, we realized that people were not prepared for it. A major obstacle is that there is no capacity to produce the vaccines that are needed. Countries that can not guarantee their own vaccine production are the ones that suffer the most from the disease, “says Sahin.